HPV and RAD51 as Prognostic Factors for Survival in Inoperable Oral and Oropharyngeal Cancer in Patients Unfit for Chemotherapy Treated with Hyperfractionated Radiotherapy.

Publication

HPV and RAD51 as Prognostic Factors for Survival in Inoperable Oral and Oropharyngeal Cancer in Patients Unfit for Chemotherapy Treated with Hyperfractionated Radiotherapy.

Journal Paper/Review - Feb 14, 2023

Zděblová Čermáková Zuzana, Hurník Pavel, Konvalinka David, Štembírek Jan, Paračková Tereza, Resová Kamila, Cvek Jakub, Blažek Tomáš, Knybel Lukáš, Formánek Martin, Gachechiladze Mariam, Jörger Markus, Soltermann Alex, Škarda Jozef, Motyka Oldřich, Janoutová Jana

Citation

Zděblová Čermáková Z, Hurník P, Konvalinka D, Štembírek J, Paračková T, Resová K, Cvek J, Blažek T, Knybel L, Formánek M, Gachechiladze M, Jörger M, Soltermann A, Škarda J, Motyka O, Janoutová J. HPV and RAD51 as Prognostic Factors for Survival in Inoperable Oral and Oropharyngeal Cancer in Patients Unfit for Chemotherapy Treated with Hyperfractionated Radiotherapy. Medicina (Kaunas) 2023; 59

Type

Journal Paper/Review (English)

Journal

Medicina (Kaunas) 2023; 59

Publication Date

Feb 14, 2023

Issn Electronic

1648-9144

Brief description/objective

The incidence of advanced oral cavity and oropharyngeal cancers is generally high. Treatment outcomes for patients, especially those unfit for comprehensive cancer treatment, are unsatisfactory. Therefore, the search for factors to predict response to treatment and increase overall survival is underway.